PDL BioPharma, Inc. Finite-Lived Intangible Asset, Expected Amortization, Year Three

PDL BioPharma, Inc. had Finite-Lived Intangible Asset, Expected Amortization, Year Three of $1.12 million as of 2020-06-30, per its 10-Q filed 2020-08-07.

Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree · last filed 2020-08-07

2020-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year Three $1.12M.
2020-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $1.06M.
2019-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Three $1.06M; Finite-Lived Intangible Asset, Expected Amortization, Year Three as first filed $2.62M.
2019-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year Three $6.18M.

Period end	Finite-Lived Intangible Asset, Expected Amortization, Year Three	Finite-Lived Intangible Asset, Expected Amortization, Year Three as first filed
2020-06-30	$1.12M 10-Q · filed 2020-08-07
2020-03-31	$1.06M 10-Q · filed 2020-05-11
2019-12-31	$1.06M 8-K · filed 2020-06-29	$2.62M 10-K · filed 2020-03-11
2019-09-30	$6.18M 10-Q · filed 2019-11-06
2019-06-30	$6.36M 10-Q · filed 2019-08-07
2019-03-31	$6.21M 10-Q · filed 2019-05-09
2018-12-31	$6.21M 10-K · filed 2019-03-15
2018-09-30	$6.21M 10-Q · filed 2018-11-07
2018-06-30	$6.21M 10-Q · filed 2018-08-09
2018-03-31	$25.25M 10-Q · filed 2018-05-09
2017-12-31	$24.95M 10-K · filed 2018-03-16
2017-09-30	$24.95M 10-Q · filed 2017-11-13
2017-03-31	$24.06M 10-Q · filed 2017-05-03
2016-12-31	$24.06M 10-K · filed 2017-03-01
2016-09-30	$24.06M 10-Q · filed 2016-11-03
2014-03-31	$32.66M 10-Q · filed 2014-05-12
2013-12-31	$33.18M 10-K · filed 2014-03-03